AQST

AQST is a pre-approval, single-catalyst biotech story where the catalyst just broke against it. The 10-K discloses a Complete Response Letter from the FDA dated January 30, 2026 for Anaphylm — the epinephrine film that is the entire equity thesis — and management concedes it must still generate additional clinical and human-factors data (including PK/PD comparability) to address the FDA's identified deficiencies. That converts a near-term approval bet into an open-ended, uncertain resubmission timeline. Meanwhile the revenue-generating base is eroding: FY2025 revenue fell 22.6% to $44.5M, driven partly by Libervant losing U.S. market access after an April 2025 court case. You are paying 11.5x sales for a shrinking top line whose growth was supposed to come from a product the FDA just rejected.

The balance sheet is the disqualifier. Stockholders' equity is negative at -$33.7M against $194M of liabilities (liabilities/equity of -5.77x is a mechanical flag that book equity is gone), and retained deficit stands at -$447M. Operating cash flow was -$52.4M in FY2025 and losses are widening — net loss of -$83.8M (operating margin -159.5%, net margin -188.1%). The $121M cash pile looks reassuring until you read that quarterly principal amortization on the 13.5% Notes begins in June 2026 unless refinanced, and management explicitly states it 'need[s] to raise substantial funds in the future' to commercialize Anaphylm if approved. With shares already up 23.4% YoY and management flagging that new capital could cause 'substantial dilution,' the equity holder is squeezed between cash burn, a punitive debt coupon, and forced issuance into a post-CRL stock.